ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0271

External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus

Alicia Malone1, Alexandra Legge1 and John Hanly1, 1Dalhousie University, Halifax, NS, Canada

Meeting: ACR Convergence 2020

Keywords: Damage Index, Mortality, Outcome measures, prognostic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility to adverse health outcomes among individuals with SLE. In this work, higher baseline SLICC-FI values were associated with increased organ damage accrual and mortality risk during follow-up. While promising, these results require external validation. The objective of the current study was to evaluate the properties of the SLICC-FI in a prevalent cohort of individuals with more longstanding SLE.

Methods: This was a secondary analysis of data from a prospective cohort of adult SLE patients at a single academic medical center. All participants met the 1997 revised ACR classification criteria for SLE and were assessed annually for medication use, comorbidities, disease activity (SLEDAI-2K), organ damage [SLICC/ACR Damage Index (SDI)], health-related quality of life [Short-Form 36 (SF-36)], and other measures.

For this analysis, we defined the baseline visit as the first visit at which both SDI and SF-36 data were available. We created an adapted version of the original SLICC-FI by modifying the definitions of individual health deficits based on data availability. Using 48 health deficits, we calculated a baseline SLICC-FI score for each patient. Vital status and SDI score at last follow-up were recorded.

Cox regression was used to estimate the association between baseline SLICC-FI values and mortality risk. Negative binomial regression was used to estimate the association of baseline SLICC-FI values with the rate of change in SDI scores per patient-year of follow-up. Multivariable models adjusted for relevant baseline variables.

Results: The 329 eligible SLE patients (96% of cohort) were mostly female (88%) with mean (SD) age 43.9 (14.4) years and median (IQR) disease duration 3.4 (1.2-13.3) years at baseline. Mean (SD) baseline SLICC-FI score was 0.17 (0.08), with 94 patients (28.6%) classified as frail (SLICC-FI > 0.21).

Forty deaths occurred during mean (SD) follow-up of 10 (5.5) years. Mortality risk was significantly higher among frail individuals (Figure 1). Higher baseline SLICC-FI values (per 0.05 units) were associated with increased mortality risk (Hazard Ratio 1.42; 95% CI 1.14-1.78), after adjusting for age, sex, education, SLE medication use, disease duration, smoking status, and baseline SDI (Table 1).

There were 133 patients with an increase in SDI score during follow-up. Higher baseline SLICC-FI values (per 0.05 units) were associated with increased damage accrual over time (Incidence Rate Ratio 1.19; 95% CI 1.09-1.31), after adjusting for age, sex, corticosteroid use, disease duration, smoking status, and baseline SDI (Table 2).

These associations between baseline SLICC-FI values and adverse health outcomes persisted when inception patients (disease duration < 15 months at enrolment) were excluded, and when items related to organ damage were omitted from the SLICC-FI.

Conclusion: Frailty, measured using the SLICC-FI, predicts organ damage accrual and mortality risk among individuals with established SLE. This external validation study provides additional support for the SLICC-FI as a useful prognostic tool in SLE.


Disclosure: A. Malone, None; A. Legge, None; J. Hanly, None.

To cite this abstract in AMA style:

Malone A, Legge A, Hanly J. External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/external-validation-of-the-systemic-lupus-international-collaborating-clinics-frailty-index-slicc-fi-as-a-predictor-of-mortality-and-organ-damage-accrual-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-of-the-systemic-lupus-international-collaborating-clinics-frailty-index-slicc-fi-as-a-predictor-of-mortality-and-organ-damage-accrual-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology